Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT06253520	TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer	Phase Phase 1	Date Added 2024-02-12	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Aldesleukin, Cyclophosphamide, Fludarabine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06043713	TitleAutologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations	Phase Phase 1	Date Added 2023-09-21	Location Washington, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Bendamustine, Cyclophosphamide, Fludarabine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03638206	TitleAutologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	Phase Phase 1/Phase 2	Date Added 2018-08-20	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs CAR-T cell immunotherapy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05141474	TitleAssessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors	Phase Early Phase 1	Date Added 2021-12-02	Location Spain	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03832855	TitleAssessing the Immunogenicity of pING-hHER3FL	Phase Phase 1	Date Added 2019-02-06	Location North Carolina, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs pING-hHER3FL	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03829462	TitleAssessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients	Phase Phase 3	Date Added 2019-02-04	Location France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Irinotecan, Regorafenib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05464030	TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	Phase Phase 1	Date Added 2022-07-19	Location California, United States Rhode Island, United States Texas, United States Canada Japan Korea, Republic of Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs M9140	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04432857	TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors	Phase Phase 1	Date Added 2020-06-16	Location Missouri, United States Texas, United States Utah, United States Virginia, United States France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs AN0025, Pembrolizumab	Tags MSS/ MMRp
NCT ID NCT04660812	TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.	Phase Phase 1, Phase 2	Date Added 2020-12-09	Location Alabama, United States Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy Korea, Republic of Spain United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab	Tags MSS/ MMRp
NCT ID NCT03994601	TitleAn Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers	Phase Phase 1	Date Added 2019-06-21	Location California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs BMS-986288, Nivolumab, Opdivo	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 221 to 230 of 299 entries